[THE INVESTOR] GC’s blood products and vaccines will propel its fourth-quarter earnings, said Cape Investment and Securities on Nov. 29 maintaining a “buy” recommendation.
Its revenue will rise 6.3 percent on-year to 296.2 billion won (US$264.13 million) and operating profit by 400 percent to 9 billion won. Its core business will grow while vaccine department will recover as supply of new products normalizes. Its attempt to enter the US market is also worthy of attention. The company’s immunoglobulin therapy not yet gained approval from the US Food and Drug Administration and the results of refilling additional data will be available in six months, said analyst Kim Hyeong-su.
Its blood product factory in Canada will start operating in 2020, and it has opened two related facilities in the US seeking to secure stable plasma inventory, said the analyst.
By Hwang You-mee (firstname.lastname@example.org)